International Stem Cell Corporation (ISCO) Develop
Post# of 124
Posted On: 03/24/2016 7:48:46 PM
International Stem Cell Corporation (ISCO) Developing Therapeutic and Biomedical Products on a Global Scale
International Stem Cell Corporation (OTCQB: ISCO) is a company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development of cell-based research and cosmetic products leading to commercialization. ISCO’s core technology, parthenogenesis, is achieved through the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid the ethical issues associated with the use or destruction of viable human embryos. Company scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of both genders and all ages and racial background with minimal risk of immune rejection after transplantation. hpSCs deliver the potential to create the first true stem cell bank, UniStemCell™.
The company’s resolve to be a leader in the field of restorative medicine is seen in its partnership with The Florey Institute of Neuroscience and Mental Health, a globally-recognized brain research center. The agreement drives both parties to launch phase I/IIa clinical trials on the effects of human parthenogenetic stem cells in individuals living with Parkinson’s disease (PD).
The Florey Institute’s credibility is undeniable. The institute employs a staff of over 500, with its scientists comprising the largest neuroscience research team in Australia. Work is conducted on a range of serious diseases, including epilepsy, stroke, PD, Alzheimer’s, traumatic brain and spinal cord injury, multiple sclerosis, depression, Huntington’s disease, motor neuron disease, schizophrenia, mental illness and a variety of addictions.
ISCO’s human cell culture products are made up of adult stem cells and reagents for regenerative medicine integral in the study of human renal and bladder diseases and prostate disease, as well as human corneal cells present in corneal disease and other cell culture reagents and supplements for the growth and freezing of human cells. International Stem Cell Corp. promotes and sells skincare products through its website and distribution channels and human cell culture products through its sales force, OEM partners, and brand distributors. The company is headquartered in Carlsbad, California, and was founded in 2001.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
International Stem Cell Corporation (OTCQB: ISCO) is a company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development of cell-based research and cosmetic products leading to commercialization. ISCO’s core technology, parthenogenesis, is achieved through the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid the ethical issues associated with the use or destruction of viable human embryos. Company scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of both genders and all ages and racial background with minimal risk of immune rejection after transplantation. hpSCs deliver the potential to create the first true stem cell bank, UniStemCell™.
The company’s resolve to be a leader in the field of restorative medicine is seen in its partnership with The Florey Institute of Neuroscience and Mental Health, a globally-recognized brain research center. The agreement drives both parties to launch phase I/IIa clinical trials on the effects of human parthenogenetic stem cells in individuals living with Parkinson’s disease (PD).
The Florey Institute’s credibility is undeniable. The institute employs a staff of over 500, with its scientists comprising the largest neuroscience research team in Australia. Work is conducted on a range of serious diseases, including epilepsy, stroke, PD, Alzheimer’s, traumatic brain and spinal cord injury, multiple sclerosis, depression, Huntington’s disease, motor neuron disease, schizophrenia, mental illness and a variety of addictions.
ISCO’s human cell culture products are made up of adult stem cells and reagents for regenerative medicine integral in the study of human renal and bladder diseases and prostate disease, as well as human corneal cells present in corneal disease and other cell culture reagents and supplements for the growth and freezing of human cells. International Stem Cell Corp. promotes and sells skincare products through its website and distribution channels and human cell culture products through its sales force, OEM partners, and brand distributors. The company is headquartered in Carlsbad, California, and was founded in 2001.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
(0)
(0)